Cargando…

Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer

Immune checkpoint inhibitors (ICIs) are gradually replacing chemotherapy as the cornerstone of the treatment of advanced malignant tumors because of their long-lasting and significant effect in different tumor types and greatly prolonging the survival time of patients. However, not all patients can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ding, Peng, Wen, Lu, Tong, Fan, Zhang, Ruiguang, Huang, Yu, Dong, Xiaorong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	OAE Publishing Inc. 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992596/ https://www.ncbi.nlm.nih.gov/pubmed/35582541 http://dx.doi.org/10.20517/cdr.2021.104

Ejemplares similares

The Research Progress of PD-1/PD-L1 Inhibitors Enhancing Radiotherapy Efficacy
por: Wen, Lu, et al.
Publicado: (2021)

Immune checkpoint inhibitors in the onset of myasthenia gravis with hyperCKemia
por: Takamatsu, Koutaro, et al.
Publicado: (2018)

Hyper‐progressive disease after immune checkpoint inhibitor in SMARCA4‐deficient small‐cell lung carcinoma
por: Chiba, Yosuke, et al.
Publicado: (2020)

T Cell-Mediated Tumor Killing-Related Classification of the Immune Microenvironment and Prognosis Prediction of Lung Adenocarcinoma
por: Ding, Peng, et al.
Publicado: (2022)

The Predictive Value of PAK7 Mutation for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Cancer
por: Zeng, Hao, et al.
Publicado: (2022)

Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies
por: Ronen, Daniel, et al.
Publicado: (2022)

Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer
por: Iranzo, Patricia, et al.
Publicado: (2022)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

Mechanisms of resistance to immune checkpoint inhibitors
por: Jenkins, Russell W, et al.
Publicado: (2018)

Mechanism of resistance to immune checkpoint inhibitors
por: Pandey, Manu R., et al.
Publicado: (2019)

Mechanisms of resistance to immune checkpoint inhibitors
por: Nagasaki, Joji, et al.
Publicado: (2022)

Immune checkpoint inhibitor combination therapy for gastric cancer: Research progress
por: Song, Xiaoxu, et al.
Publicado: (2020)

Immune checkpoint inhibitors: recent progress and potential biomarkers
por: Darvin, Pramod, et al.
Publicado: (2018)

Progressive Multifocal Leukoencephalopathy Treated by Immune Checkpoint Inhibitors
por: Boumaza, Xavier, et al.
Publicado: (2022)

Progress and Challenges of Immune Checkpoint Inhibitor-Induced Hypophysitis
por: Chen, Piaohong, et al.
Publicado: (2023)

Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management
por: Zhou, Yu-Wen, et al.
Publicado: (2019)

Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors
por: Perrier, Alexandre, et al.
Publicado: (2020)

Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
por: Westdorp, Harm, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-Induced Diabetes Mellitus: Potential Role of T Cells in the Underlying Mechanism
por: Mourad, Diane, et al.
Publicado: (2021)

Hyperprogression under treatment with immune-checkpoint inhibitors in patients with gastrointestinal cancer: A natural process of advanced tumor progression?
por: Wang, Mo-Xuan, et al.
Publicado: (2022)

Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects
por: Zou, Wenlu, et al.
Publicado: (2021)

First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress
por: Huang, Zhangfeng, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors and Neurotoxicity
por: Zhao, Zhiyi, et al.
Publicado: (2021)

Is Weak Acid Beneficial for Addressing Checkpoint Inhibitor–Triggered Cancer Hyper Progression in Anti-PD1/PD-L1 Immunotherapies?
por: Wan, Yulin, et al.
Publicado: (2020)

Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma
por: Zeng, Zhu, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges
por: Liu, Hao-Tian, et al.
Publicado: (2021)

Research progress in immune checkpoint inhibitors for lung cancer in China
por: Gan, Jiadi, et al.
Publicado: (2021)

Clinical Research on the Mechanisms Underlying Immune Checkpoints and Tumor Metastasis
por: Tang, Xi-Yang, et al.
Publicado: (2021)

Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies
por: Zhou, Binghan, et al.
Publicado: (2021)

Mechanisms of immune checkpoint inhibitor-mediated liver injury
por: Shojaie, Layla, et al.
Publicado: (2021)

Immune checkpoint inhibitors
por: Hui, Enfu
Publicado: (2019)

Immune checkpoint inhibitors
por: Kroemer, Guido, et al.
Publicado: (2021)

Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
por: Yang, Fan, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Special Populations
por: Shan, Qianyun, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-related Endocrinopathies
por: Lu, Difei, et al.
Publicado: (2022)

Immune checkpoint inhibitors in cancer therapy
por: Webb, Eika S., et al.
Publicado: (2018)

Hyperprogression After Immune-Checkpoint Inhibitor Treatment: Characteristics and Hypotheses
por: Zang, Hongjing, et al.
Publicado: (2020)

The Mechanism and Management of Adverse Cardiac Reactions Induced by Immune Checkpoint Inhibitors Therapy
por: Rong, Fangning, et al.
Publicado: (2020)

Cutaneous immune-related adverse events to immune checkpoint inhibitors: from underlying immunological mechanisms to multi-omics prediction
por: Cao, Ting, et al.
Publicado: (2023)

Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities
por: Jiao, Ruidi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f7lqfuuj1gki528og87hdgc8cr